<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02609126</url>
  </required_header>
  <id_info>
    <org_study_id>EP-104IAR-101</org_study_id>
    <nct_id>NCT02609126</nct_id>
  </id_info>
  <brief_title>Safety Study of a Long-Acting Injectable Steroid to Treat Knee Osteoarthritis</brief_title>
  <acronym>STEPUP</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial Evaluating the Pharmacokinetics, Safety and Preliminary Efficacy of EP-104IAR (Long-Acting Fluticasone Propionate) in Patients With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eupraxia Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syreon Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eupraxia Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to understand the pharmacokinetics of EP-104IAR and to
      determine whether it is safe to use in patients with osteoarthritis (OA) of the knee. The
      study will also provide some preliminary insights into whether the experimental treatment
      reduces pain in the knee.

      Osteoarthritis is the most common joint disease, affecting over 20 million people in the US
      alone. Currently, pain treatments that are injected directly into the knee often work for
      only a short time and may also have side effects within the rest of the body. The
      experimental treatment is a steroid that is in the same family of drugs as the most common
      current injectable treatments for knee osteoarthritis. For this study, the drug is coated
      with a polymer intended to prolong the time it stays inside the knee and lessen potential
      side effects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">December 28, 2017</completion_date>
  <primary_completion_date type="Actual">December 28, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of fluticasone propionate</measure>
    <time_frame>Up to 42 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fluticasone propionate concentrations in synovial fluid</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of fluticasone propionate</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Up to 42 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in clinical laboratory parameters: hematology, chemistry (including cortisol) and urinalysis</measure>
    <time_frame>Up to 42 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to baseline pain in patient-reported Pain Numerical Rating Scale for Index knee</measure>
    <time_frame>Weekly up to 42 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patient-reported Pain Numerical Rating Scale for Index knee</measure>
    <time_frame>Weekly up to 42 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patient-reported Global Assessment of Arthritis</measure>
    <time_frame>Up to 42 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patient-reported Western Ontario and McMaster Universities Arthritis Index (WOMAC)</measure>
    <time_frame>Up to 42 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patient-reported Short Form - 36 quality of life scores</measure>
    <time_frame>Up to 42 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Physician's Global Assessment of Arthritis</measure>
    <time_frame>Up to 42 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>EP-104IAR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg EP-104IAR in 4 mL carrier fluid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 mL carrier fluid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EP-104IAR</intervention_name>
    <description>Single, ultrasound-guided injection of EP-104IAR into the knee</description>
    <arm_group_label>EP-104IAR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Single, ultrasound-guided injection of vehicle placebo into the knee</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  OA of Index Knee ≥6 months

          -  Kellgren Lawrence Grade 2 or 3

          -  Patient-reported pain (PtPain) of Index Knee ≥4 but ≤9

          -  PtPain of non-Index Knee &lt;4

          -  BMI ≦ 40 kg/m2

        Exclusion Criteria:

          -  Intra-articular joint injection in the Index Knee within the past 8 weeks for
             glucocorticoids and 6 months for hyaluronic acid

          -  Insulin-dependent diabetes

          -  Active infection

          -  Pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Helliwell, MD FRCPC</last_name>
    <role>Study Director</role>
    <affiliation>Eupraxia Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rebalance MD</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Studies in Family Medicine</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 3K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fowler Kennedy Sports Medicine Clinic</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 3K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

